Canada leads in terms of the post-market surveillance area, in terms of comparative safety and effectiveness of drugs. We are the world's leader in the analysis of that. We have the drug safety and effectiveness network, funded through Health Canada, which uses the repositories of population-based data in each and every province to answer questions about the concerns about the safety of drugs. This is something that is a huge success story internationally for Canada.
We don't have the richest data. We don't have patient-reported outcomes in there. I think we need that. We don't have information such as lab values and other such rich clinical data.
I guess what I am trying to say is that we are collecting that. We put it in repositories, and then we don't use it. We have the capacity. Now it is just the political leadership, I think, quite frankly, that we need.
We do have a central body that does a common drug review. Ontario and Quebec do their own review, I think more for political reasons than anything else.
What we don't have is the machinery for this proactive post-market surveillance system, a strategy that puts it in place and someone to lead it. Who is going to be responsible for that? We have all the parts. We just need the political leadership and the strategy.
This international network is absolutely going to be essential for rare diseases, but the other thing that is important to consider is that there may be some real benefit in some national role for negotiating prices. I think everybody would be appreciative of that, especially for what you might call the bare essentials. Absolutely, we could do so much better.
I forgot my last point, so I will just stop there.